Protocol Ledger

NCT03910244 · Phase II · COMPLETED

Pomalidomide for the Treatment of Bleeding in HHT

Interventional Phase II clinical trial protocol NCT03910244 sponsored by The Cleveland Clinic in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-17 Enrollment: 145 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03910244
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)145 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03910244
Protocol FieldVerified Registry Value
NCT IdentifierNCT03910244
Consolidated Lead SponsorThe Cleveland Clinic
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment145 participants (ACTUAL)
Registered Start Date2019-10-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Cleveland Clinic across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI